Aliases & Classifications for Sleep Apnea

MalaCards integrated aliases for Sleep Apnea:

Name: Sleep Apnea 12 50 28 40 14 59
Sleep Apnea Syndromes 69

Classifications:



External Ids:

Disease Ontology 12 DOID:0050847

Summaries for Sleep Apnea

NINDS : 50 Sleep apnea is a common sleep disorder characterized by brief interruptions of breathing during sleep.  These episodes usually last 10 seconds or more and occur repeatedly throughout the night.  People with sleep apnea will partially awaken as they struggle to breathe, but in the morning they will not be aware of the disturbances in their sleep.  The most common type of sleep apnea is obstructive sleep apnea (OSA), caused by relaxation of soft tissue in the back of the throat that blocks the passage of air.  Central sleep apnea (CSA) is caused by irregularities in the brain’s normal signals to breathe.  Most people with sleep apnea will have a combination of both types.  The hallmark symptom of the disorder is excessive daytime sleepiness. Additional symptoms of sleep apnea include restless sleep, loud snoring (with periods of silence followed by gasps), falling asleep during the day, morning headaches, trouble concentrating, irritability, forgetfulness, mood or behavior changes, anxiety, and depression.  Not everyone who has these symptoms will have sleep apnea, but it is recommended that people who are experiencing even a few of these symptoms visit their doctor for evaluation.  Sleep apnea is more likely to occur in men than women, and in people who are overweight or obese.

MalaCards based summary : Sleep Apnea, also known as sleep apnea syndromes, is related to central sleep apnea and obesity-hypoventilation syndrome, and has symptoms including disruption of 24 hour sleep wake cycle, unspecified, hypersomnia with sleep apnea, unspecified and insomnia with sleep apnea, unspecified. An important gene associated with Sleep Apnea is AHDC1 (AT-Hook DNA Binding Motif Containing 1), and among its related pathways/superpathways are Signaling by GPCR and Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.. The drugs Cafcit Injection and Donepezil have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and homeostasis/metabolism

Disease Ontology : 12 A sleep disorder characterized by repeated cessation and commencing of breathing that repeatedly disrupts sleep.

MedlinePlus : 40 Sleep apnea is a common disorder that causes your breathing to stop or get very shallow. Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. The most common type is obstructive sleep apnea. It causes your airway to collapse or become blocked during sleep. Normal breathing starts again with a snort or choking sound. People with sleep apnea often snore loudly. However, not everyone who snores has sleep apnea. You are more at risk for sleep apnea if you are overweight, male, or have a family history or small airways. Children with enlarged tonsils or adenoids may also get it. Doctors diagnose sleep apnea based on medical and family histories, a physical exam, and sleep study results. When your sleep is interrupted throughout the night, you can be drowsy during the day. People with sleep apnea are at higher risk for car crashes, work-related accidents, and other medical problems. If you have it, it is important to get treatment. Lifestyle changes, mouthpieces, surgery, and breathing devices can treat sleep apnea in many people. NIH: National Heart, Lung, and Blood Institute

PubMed Health : 59
About sleep apnea: Sleep apnea (AP-ne-ah) is a common disorder in which you have one or more pauses in breathing or shallow breaths while you sleep.Breathing pauses can last from a few seconds to minutes. They may occur 30 times or more an hour. Typically, normal breathing then starts again, sometimes with a loud snort or choking sound.Sleep apnea usually is a chronic (ongoing) condition that disrupts your sleep. When your breathing pauses or becomes shallow, you’ll often move out of deep sleep and into light sleep.As a result, the quality of your sleep is poor, which makes you tired during the day. Sleep apnea is a leading cause of excessive daytime sleepiness.

Wikipedia : 72 Sleep apnea, also spelled sleep apnoea, is a sleep disorder characterized by pauses in breathing or... more...

Related Diseases for Sleep Apnea

Diseases in the Sleep Apnea family:

Central Sleep Apnea

Diseases related to Sleep Apnea via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 529)
# Related Disease Score Top Affiliating Genes
1 central sleep apnea 34.6 LEP NOS3 NPPB
2 obesity-hypoventilation syndrome 32.9 ADIPOQ IL6 LEP
3 sleep disorder 32.6 CRP HCRT IL6 LEP
4 apnea, obstructive sleep 31.9 ADIPOQ AHDC1 CRP EDN1 HCRT HTR2A
5 congestive heart failure 30.8 ACE EDN1 NPPB REN
6 ischemic optic neuropathy 30.8 ACE EDN1 NOS3
7 systolic heart failure 30.7 ACE CRP IL6 NPPB
8 nonarteritic anterior ischemic optic neuropathy 30.6 ACE EDN1 NOS3
9 tonsillitis 30.4 CXCL8 IL6 TNF
10 angina pectoris 30.4 ACE CRP IL6
11 multiple symmetrical lipomatosis 30.4 ADIPOQ IL6 LEP
12 lung disease 30.4 CXCL8 EDN1 NPPB TNF
13 liver disease 30.3 ADIPOQ IL6 INS LEP TNF
14 periodontitis 30.2 CRP CXCL8 IL6 TNF
15 nonalcoholic steatohepatitis 30.2 ADIPOQ IL6 INS LEP TNF
16 kidney disease 30.2 ACE APOE EDN1 NPPB REN
17 carotid artery disease 30.2 ACE APOE CRP
18 aortic disease 30.2 APOE IL6 REN
19 arteritic anterior ischemic optic neuropathy 30.1 ACE CRP NOS3
20 coronary heart disease 1 30.1 ACE ADIPOQ APOE CRP INS
21 periodontal disease 30.1 CRP CXCL8 IL6 TNF
22 ischemia 30.1 ACE EDN1 ICAM1 NOS3
23 pneumonia 30.1 CRP CXCL8 IL6 TNF
24 interstitial lung disease 30.1 CXCL8 EDN1 IL6 TNF
25 acute respiratory distress syndrome 30.1 CXCL8 IL6 TNF
26 diastolic heart failure 30.0 ACE NOS3 NPPB
27 narcolepsy 30.0 GHRL HCRT HTR2A LEP TNF
28 fatty liver disease 30.0 ADIPOQ IL6 INS LEP LEPR TNF
29 acute myocardial infarction 30.0 ACE CRP EDN1 NPPB
30 uremia 30.0 CRP INS LEP
31 pulmonary hypertension 29.9 ACE EDN1 IL6 NOS3 NPPB REN
32 keratoconjunctivitis 29.9 CXCL8 ICAM1 TNF
33 pulmonary disease, chronic obstructive 29.9 CRP CXCL8 IL6 TNF
34 cystitis 29.9 CRP CXCL8 IL6 TNF
35 respiratory failure 29.9 ACE CRP CXCL8 EDN1 TNF
36 ischemic heart disease 29.7 ACE APOE CRP IL6 NOS3 NPPB
37 idiopathic edema 29.7 ACE ADIPOQ EDN1 INS NPPB
38 hypertrophic cardiomyopathy 29.6 ACE IGF1 IL6 NPPB TNF
39 carotid stenosis 29.6 ACE APOE CRP CXCL8 ICAM1 TNF
40 asthma 29.5 CXCL8 EDN1 ICAM1 IL6 INS LEP
41 stroke, ischemic 29.4 ACE APOE CRP NOS3 REN
42 chronic fatigue syndrome 29.4 CXCL8 IGF1 IL6 TNF
43 cerebrovascular disease 29.3 ACE APOE CRP ICAM1 IL6 INS
44 microvascular complications of diabetes 5 29.3 ACE ICAM1 IGF1 INS NOS3
45 diabetes mellitus 29.2 ACE ADIPOQ CRP IGF1 IL6 INS
46 polycystic ovary syndrome 29.2 GHRL IGF1 INS LEP
47 coronary artery anomaly 29.1 ACE ADIPOQ APOE CRP EDN1 IL6
48 arteriosclerosis 29.0 ACE ADIPOQ APOE CRP EDN1 ICAM1
49 morbid obesity 28.9 ADIPOQ CRP GHRL HCRT INS LEP
50 prader-willi syndrome 28.8 ADIPOQ GHRL HCRT IGF1 INS LEP

Comorbidity relations with Sleep Apnea via Phenotypic Disease Network (PDN):


Bronchitis Chronic Pulmonary Heart Disease
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential Hypothyroidism
Ischemic Heart Disease Pulmonary Hypertension, Primary, 1
Respiratory Failure

Graphical network of the top 20 diseases related to Sleep Apnea:



Diseases related to Sleep Apnea

Symptoms & Phenotypes for Sleep Apnea

UMLS symptoms related to Sleep Apnea:


disruption of 24 hour sleep wake cycle, unspecified, hypersomnia with sleep apnea, unspecified, insomnia with sleep apnea, unspecified, sleeplessness, excessive daytime somnolence, labored breathing, vertigo/dizziness, chronic pain, wheezing, tremor, syncope, snoring, sleep disturbances, seizures, sciatica, pain, headache, dyspnea, coughing, cheyne-stokes respiration, back pain, apnea

MGI Mouse Phenotypes related to Sleep Apnea:

43 (show all 20)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.45 IGF1 HCRT ICAM1 IL6 LEP INS
2 homeostasis/metabolism MP:0005376 10.43 EDN1 GHRL IGF1 HCRT ICAM1 IL6
3 behavior/neurological MP:0005386 10.4 GHRL HCRT HTR2A IL6 LEP INS
4 endocrine/exocrine gland MP:0005379 10.4 GHRL IGF1 HTR2A ICAM1 IL6 LEP
5 growth/size/body region MP:0005378 10.39 EDN1 IGF1 HCRT ICAM1 IL6 LEP
6 adipose tissue MP:0005375 10.33 GHRL IGF1 IL6 LEP INS LEPR
7 immune system MP:0005387 10.32 ICAM1 IGF1 IL6 LEP INS LEPR
8 digestive/alimentary MP:0005381 10.31 GHRL HTR2A ICAM1 IL6 LEP INS
9 hematopoietic system MP:0005397 10.31 ICAM1 TNF IGF1 IL6 LEP INS
10 muscle MP:0005369 10.28 IGF1 HCRT HTR2A ICAM1 IL6 LEP
11 mortality/aging MP:0010768 10.27 EDN1 ICAM1 TNF IGF1 INS IL6
12 integument MP:0010771 10.15 ICAM1 TNF IGF1 INS IL6 LEP
13 nervous system MP:0003631 10.15 ICAM1 EDN1 TNF HCRT IGF1 INS
14 liver/biliary system MP:0005370 10.13 TNF IL6 LEP INS LEPR NOS3
15 renal/urinary system MP:0005367 10.06 IGF1 IL6 LEP INS LEPR REN
16 neoplasm MP:0002006 10.01 ICAM1 TNF IGF1 IL6 LEP LEPR
17 reproductive system MP:0005389 9.96 TNF IGF1 IL6 LEP INS NOS3
18 respiratory system MP:0005388 9.81 TNF HCRT IGF1 IL6 LEP NOS3
19 skeleton MP:0005390 9.7 EDN1 IGF1 HTR2A IL6 LEP INS
20 vision/eye MP:0005391 9.23 ICAM1 TNF INS IL6 LEP NOS3

Drugs & Therapeutics for Sleep Apnea

PubMedHealth treatment related to Sleep Apnea: 59

Sleep apnea is treated with lifestyle changes, mouthpieces, breathing devices, and surgery. Medicines typically aren't used to treat the condition.The goals of treating sleep apnea are to:Restore regular breathing during sleepRelieve symptoms such as loud snoring and daytime sleepinessTreatment may improve other medical problems linked to sleep apnea, such as high blood pressure. Treatment also can reduce your risk for heart disease, stroke, and diabetes.If you have sleep apnea, talk with your doctor or sleep specialist about the treatment options that will work best for you.Lifestyle changes and/or mouthpieces may relieve mild sleep apnea. People who have moderate or severe sleep apnea may need breathing devices or surgery.If you continue to have daytime sleepiness despite treatment, your doctor may ask whether you're getting enough sleep. (Adults should get at least 7 to 8 hours of sleep; children and teens need more. For more information, go to the Health Topics Sleep Deprivation and Deficiency article.)If treatment and enough sleep don't relieve your daytime sleepiness, your doctor will consider other treatment options.

FDA approved drugs:

# Drug Name Active Ingredient(s) 17 Company Approval Date
1
Cafcit Injection 17 CAFFEINE CITRATE Roxane Laboratories September 1999

Drugs for Sleep Apnea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 446)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Donepezil Approved Phase 4 120014-06-4 3152
2
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
3
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
4
Nebivolol Approved, Investigational Phase 4 152520-56-4, 118457-14-0, 99200-09-6 71301
5
Amlodipine Approved Phase 4,Phase 2,Phase 3 88150-42-9 2162
6
Angiotensin II Approved, Investigational Phase 4,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
7
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
8
Dexlansoprazole Approved, Investigational Phase 4 138530-94-6, 103577-45-3 9578005
9
Lansoprazole Approved, Investigational Phase 4 103577-45-3 3883
10
Clonidine Approved Phase 4 4205-90-7 2803
11
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
12
Nitric Oxide Approved Phase 4 10102-43-9 145068
13
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 76631-46-4, 113775-47-6 5311068 56032 68602
14
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 2078-54-8 4943
15
Budesonide Approved Phase 4,Phase 3,Phase 1 51333-22-3 5281004 63006
16
Montelukast Approved Phase 4,Phase 3,Phase 2 158966-92-8 5281040
17
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2 59-66-5 1986
18
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2 2216-51-5 16666
19
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 1 437-38-7 3345
20
Morphine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 57-27-2 5288826
21
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
22
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2 137-58-6 3676
23
Acetaminophen Approved Phase 4,Phase 3 103-90-2 1983
24
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
25
Adalimumab Approved Phase 4 331731-18-1 16219006
26
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
27
Atropine Approved, Vet_approved Phase 4 5908-99-6, 51-55-8 174174
28
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
29
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
30
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
31
Armodafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 112111-43-0
32
Modafinil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68693-11-8 4236
33
Sodium oxybate Approved Phase 4 502-85-2 5360545
34
Zolpidem Approved Phase 4 82626-48-0 5732
35
Losartan Approved Phase 4,Phase 2 114798-26-4 3961
36
Ephedrine Approved Phase 4 299-42-3 9294
37
Pseudoephedrine Approved Phase 4 90-82-4 7028
38
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
39
Eszopiclone Approved, Investigational Phase 4,Phase 2,Early Phase 1 138729-47-2 969472
40
Norepinephrine Approved Phase 4 51-41-2 439260
41
Pantoprazole Approved Phase 4 102625-70-7 4679
42
Eplerenone Approved Phase 4 107724-20-9 443872 150310
43
Remifentanil Approved Phase 4,Early Phase 1 132875-61-7 60815
44
Phentermine Approved, Illicit Phase 4,Phase 1,Phase 2 122-09-8 4771
45
Topiramate Approved Phase 4,Phase 1,Phase 2 97240-79-4 5284627
46
Olanzapine Approved, Investigational Phase 4,Phase 1 132539-06-1 4585
47
Testosterone Approved, Investigational Phase 4 58-22-0 6013
48
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3 6740-88-1 3821
49
Desflurane Approved Phase 4 57041-67-5 42113
50
Sevoflurane Approved, Vet_approved Phase 4,Phase 3 28523-86-6 5206

Interventional clinical trials:

(show top 50) (show all 1725)

# Name Status NCT ID Phase Drugs
1 Multidisciplinary and Coordinated Follow-up Based on a Telemonitoring Web Platform for Improving CPAP Compliance in Low Cardiovascular Risk Sleep Apnea Patients : OPTISAS 1 Study Unknown status NCT01796769 Phase 4
2 Donepezil Treatment for Sleep Apnea Patients Unknown status NCT00912457 Phase 4 donepezil;placebo
3 Comparison of the Pentax AWS® With the Macintosh Laryngoscopic Intubation in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01428570 Phase 4
4 Blood Pressure Reduction Induced by CPAP in Sleep Apnea Patients at High Cardiovascular Risk : OPTISAS 2 Study Unknown status NCT01505959 Phase 4
5 Cost-utility Study of Continuous Positive Airway Pressure Treatment in Obstructive Sleep Apnea Syndrome Patients Unknown status NCT01590420 Phase 4
6 Validation of Functional Imaging as Predictive Tool for Outcome of Mandibular Replacement Appliance Therapy in Obstructive Sleep Apnea Hypopnea Syndrome Patients Unknown status NCT01524510 Phase 4
7 PROMAD: Predicting Therapeutic Outcome of Mandibular Advancement Device Treatment in Obstructive Sleep Apnea Unknown status NCT01532050 Phase 4
8 Continuous Positive Airway Pressure in Sleep Apnea Syndrome: Effects on Metabolic Syndrome and Cardiac Damage Unknown status NCT00517777 Phase 4
9 A Randomized Cross Over Trial of Two Treatments for Obstructive Sleep Apnea in Veterans With Post Traumatic Stress Disorder Unknown status NCT01535586 Phase 4
10 Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic Unknown status NCT02699125 Phase 4 Guanfacine;Hydrochlorothiazide
11 CPAP and Nebivolol in Hypertensive Obstructive Sleep Apnea (OSA) Patients. Unknown status NCT01771406 Phase 4 Nebivolol
12 The Effects of Continuous Positive Airway Pressure on Overlap Syndrome Unknown status NCT00914264 Phase 4
13 Treatment of Cheyne Stocks Respiration With Adaptive Servo Ventilation and Bilevel Ventilators in Patients With Chronic Heart Failure Unknown status NCT00725595 Phase 4
14 Intermittent Hypoxia 2: Cardiovascular and Metabolism Unknown status NCT02058823 Phase 4 Placebo;Placebo;Valsartan;Amlodipine
15 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
16 Resistant Hypertension Optimal Treatment Unknown status NCT01643434 Phase 4 Spironolactone;Clonidine
17 Nasal Continuous Positive Airway Pressure (CPAP) in Chronic Fatigue and Sleep-disordered Breathing Unknown status NCT01368718 Phase 4
18 Sleep Disordered Breathing in Transient Ischemic Attack (TIA)/Ischemic Stroke and Continuous Positive Airway Pressure (CPAP) Treatment Efficacy Unknown status NCT01097967 Phase 4
19 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
20 Obstructive Sleep Apnea in the Absence of Metabolic Syndrome Completed NCT01635010 Phase 4
21 Efficacy and Safety of Adalimumab in Patients With Psoriasis and Obstructive Sleep Apnea Completed NCT01181570 Phase 4 Adalimumab;Placebo
22 Sleep Apnea and Oxidative Stress and Nitric Oxide Completed NCT00547937 Phase 4
23 Sugammadex Compared With Neostigmin/Atropin for Neuromuscular Block Reversal in Patients With Obstructive Sleep Apnea Completed NCT02160223 Phase 4 Sugammadex;Neostigmine
24 The Impact of Arousal Threshold in Obstructive Sleep Apnea Completed NCT02264353 Phase 4 Donepezil;placebo
25 Sodium-Restricted Diet and Diuretic in the Treatment of Severe Sleep Apnea Completed NCT01945801 Phase 4 Lasilactone;Placebo
26 Cardiac Resynchronisation Therapy in Combination With Overdrive Pacing in the Treatment of Central Sleep Apnea in CHF Completed NCT00551499 Phase 4
27 Cardiovascular Impact of Obstructive Sleep Apnea Treatment in Normotensive Patients Completed NCT00741520 Phase 4
28 Study to Determine the Effectiveness of Pillar Palatal Implants to Treat Obstructive Sleep Apnea Completed NCT00307957 Phase 4
29 Serotonin and the Upper Airway in Obstructive Sleep Apnea Completed NCT00100464 Phase 4 Paroxetine;5HTP
30 Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients Completed NCT00086281 Phase 4 Xyrem (X);Zolpidem (Z);Modafinil (M);Placebo (P)
31 Ventricular Arrhythmias Incidence According to Sleep Apnea Syndrome in Implantable Cardioverter-Defibrillator (ICD) Patients Completed NCT00708786 Phase 4
32 Dexmedetomidine and Propofol in Children With History of Obstructive Sleep Apnea Completed NCT01344759 Phase 4 Dexmedetomidine;Propofol
33 Randomized Study of Provent Versus Sham Device to Treat Obstructive Sleep Apnea Completed NCT00772044 Phase 4
34 Efficacy of Oral Leukotriene in Long Term Therapy of Mild and Moderate Obstructive Sleep Apnea Syndrome in Children Completed NCT00912171 Phase 4 budesonide (Aircort 50 nasal spray);montelukast (Singulair)
35 Losartan in Hypertensive Men and Women With Sleep Apnea Before and on Continuous Positive Airway Pressure (CPAP) Treatment Completed NCT00701428 Phase 4 Losartan
36 Nasal Decongestion and Obstructive Sleep Apnea Completed NCT00630474 Phase 4 xylometazoline
37 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
38 Nasal Budesonide in Children With Rhinitis and/or Mild Obstructive Sleep Apnea Syndrome Completed NCT00560586 Phase 4 Budesonide;placebo
39 Sleep Apnea. Concordance Between Non-reference and Reference Centres Completed NCT00424658 Phase 4
40 CPAP in Diabetes Type 2 Patients With Sleep Apnea Completed NCT01801150 Phase 4
41 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
42 The Endothelium Dysfunction in Patients of Obstructive Sleep Apnea Syndrome Completed NCT01699126 Phase 4 Statin
43 Sleep Apnea-hypopnea Syndrome (SAHS) and Ventricular Arrhythmias Completed NCT00765713 Phase 4
44 Early Signs of Atherosclerosis in Obstructive Sleep Apnea: Effects of Treatment Completed NCT00400543 Phase 4
45 Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome Completed NCT00603044 Phase 4 fluticasone furoate
46 Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea Completed NCT00519597 Phase 4
47 Effect of Continuous Positive Airway Pressure (CPAP) on Hypertension and Cardiovascular Morbidity-Mortality in Patients With Sleep Apnea and no Daytime Sleepiness Completed NCT00127348 Phase 4
48 Efficacy of CPAP Treatment on Blood Pressure of Resistant Hypertension Patients With Obstructive Sleep Apnea Syndrome Completed NCT01508754 Phase 4
49 Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Completed NCT00518986 Phase 4 armodafinil;placebo
50 Automate Detection of Sleep Apnea by ApneascanTM Completed NCT02045173 Phase 4

Search NIH Clinical Center for Sleep Apnea

Genetic Tests for Sleep Apnea

Genetic tests related to Sleep Apnea:

# Genetic test Affiliating Genes
1 Sleep Apnea 28

Anatomical Context for Sleep Apnea

MalaCards organs/tissues related to Sleep Apnea:

38
Heart, Testes, Endothelial, Lung, Brain, Liver, Kidney

Publications for Sleep Apnea

Articles related to Sleep Apnea:

(show top 50) (show all 1726)
# Title Authors Year
1
Increasing cerebral blood flow reduces the severity of central sleep apnea at high altitude. ( 29389246 )
2018
2
Chiari type 1 malformation associated with central sleep apnea after high dose growth hormone (GH) therapy in a 12-year-old boy: A case report. ( 29403156 )
2018
3
Alterations of IGF-1, complement C3 and superoxide dismutase in patients with moderate-to-severe obstructive sleep apnea hypopnea syndrome. ( 29441807 )
2018
4
Central Sleep Apnea with Cheyne-Stokes Breathing in Heart Failure - From Research to Clinical Practice and Beyond. ( 29411336 )
2018
5
The effect of positive and negative message framing on short term continuous positive airway pressure compliance in patients with obstructive sleep apnea. ( 29445540 )
2018
6
Obstructive Sleep Apnea Screening AmongA Surgical Patients: A Quality Improvement Project. ( 29429821 )
2018
7
Association of Adenotonsillectomy With Blood Pressure Among Hypertensive and Nonhypertensive Children With Obstructive Sleep Apnea. ( 29450504 )
2018
8
Adaptive servo-ventilation and sleep quality in treatment emergent central sleep apnea and central sleep apnea in patients with heart disease and preserved ejection fraction. ( 29372314 )
2018
9
Pre- and post-operative evaluation of the frequency of nocturnal enuresis and Modified Pediatric Epworth Scale in pediatric obstructive sleep apnea patients. ( 29447815 )
2018
10
Evaluation of a Multichannel Non-Contact ECG System and Signal Quality Algorithms for Sleep Apnea Detection and Monitoring. ( 29438344 )
2018
11
Kinesthetic stimulation for obstructive sleep apnea syndrome: An "on-off" proof of concept trial. ( 29449609 )
2018
12
Knowledge Gaps in the Perioperative Management of Adults with Obstructive Sleep Apnea and Obesity Hypoventilation Syndrome. An Official American Thoracic Society Workshop Report. ( 29388810 )
2018
13
Microstructural cerebral lesions are associated with the severity of central sleep apnea with Cheyne-Stokes-respiration in heart failure and are modified by PAP-therapy. ( 29102807 )
2018
14
Comorbid obstructive sleep apnea and increased risk for sickle cell disease morbidity. ( 29450676 )
2018
15
Risk of obstructive sleep apnea in open-angle glaucoma versus controls using the STOP-Bang questionnaire. ( 29426446 )
2018
16
Lithuanian dentists' knowledge, attitudes, and clinical practices regarding obstructive sleep apnea: A nationwide cross-sectional study. ( 29431599 )
2018
17
Intermittent hypoxia promotes melanoma lung metastasis via oxidative stress and inflammation responses in a mouse model of obstructive sleep apnea. ( 29433520 )
2018
18
Correlations between pediatric obstructive sleep apnea and longitudinal growth. ( 29447889 )
2018
19
Determinants of sleepiness in obstructive sleep apnea. ( 29444292 )
2018
20
Mandibular positioning techniques to improve sleep quality in patients with obstructive sleep apnea: current perspectives. ( 29440942 )
2018
21
Correction to: Obstructive sleep apnea does not impair cardiorespiratory responses to progressive exercise performed until exhaustion in hypertensive elderly. ( 29442289 )
2018
22
Classification methods to detect sleep apnea in adults based on respiratory and oximetry signals: a systematic review. ( 29446755 )
2018
23
Improvement of Neuropathy Symptoms With Treatment of Obstructive Sleep Apnea in a Patient With Charcot-Marie-Tooth Disease. ( 29246265 )
2018
24
Comorbid insomnia and sleep apnea in Veterans with post-traumatic stress disorder. ( 29330769 )
2018
25
IGF-1-based screening reveals a low prevalence of acromegaly in patients with obstructive sleep apnea. ( 29388045 )
2018
26
Utility of bispectrum in the screening of pediatric sleep apnea-hypopnea syndrome using oximetry recordings. ( 29428066 )
2018
27
A Modified Definition for Obstructive Sleep Apnea in Home Sleep Apnea Testing after Stroke or Transient Ischemic Attack. ( 29428326 )
2018
28
Determinants of obstructive sleep apnea syndrome: Pro-inflammatory state and dysfunction of high-density lipoprotein. ( 28935145 )
2017
29
The Erlangen Questionnaire: a new 5-item screening tool for obstructive sleep apnea in a sleep clinic population - A prospective, double blinded study. ( 28925472 )
2017
30
Low leptin concentration may identify heart failure patients with central sleep apnea. ( 28643476 )
2017
31
Gray Matter Hypertrophy and Thickening with Obstructive Sleep Apnea in Middle-aged and Older Adults. ( 28060546 )
2017
32
Investigation of the link between fluid shift and airway collapsibility as a mechanism for obstructive sleep apnea in congestive heart failure. ( 28057850 )
2017
33
Predominant obstructive or central sleep apnea in patients with atrial fibrillation: influence of characterizing apneas versus apneas and hypopneas. ( 28899542 )
2017
34
Magnetic resonance imaging of the upper airway in patients with quadriplegia and obstructive sleep apnea. ( 29082563 )
2017
35
Chiari 1 Malformation in a Child with Febrile Seizures, Parasomnias, and Sleep Apnea Syndrome. ( 29391961 )
2017
36
Central sleep apnea during continuous positive airway pressure therapy in obstructive sleep apnea patients: from the compliance to adaptation, maladaptation and reflexes. ( 29268457 )
2017
37
Diastolic Blood Pressure Rises with the Exacerbation of Obstructive Sleep Apnea in Males. ( 28922573 )
2017
38
Central Sleep Apnea in Patients with Congestive Heart Failure. ( 28477776 )
2017
39
Adenotonsillectomy outcomes in children with sleep apnea and narcolepsy. ( 28802388 )
2017
40
Is obstructive sleep apnea associated with the presence of intracranial cerebral atherosclerosis? ( 28168435 )
2017
41
Endothelin contributes to the blood pressure rise triggered by hypoxia in severe obstructive sleep apnea. ( 27906839 )
2017
42
Caveolin-1 polymorphisms in patients with severe obstructive sleep apnea. ( 27321703 )
2017
43
REM sleep behavior disorder and obstructive sleep apnea: does one "evil" make the other less or more "evil"? ( 28754242 )
2017
44
Obstructive sleep apnea and rhonchopathy are associated with downregulation of trefoil factor family peptide 3 (TFF3)-Implications of changes in oral mucus composition. ( 29028798 )
2017
45
Oral appliance therapy versus nasal continuous positive airway pressure in obstructive sleep apnea: a randomized, placebo-controlled trial on psychological distress. ( 28083705 )
2017
46
Central Sleep Apnea and Stiff Person Syndrome: A Case Report. ( 28358591 )
2017
47
Risk of obstructive sleep apnea among patients with Cushing's syndrome: a nationwide longitudinal study. ( 28735920 )
2017
48
A comparison of two screening tools for paediatric obstructive sleep apnea. ( 28944605 )
2017
49
Association between central sleep apnea and left ventricular structure: the Multi-Ethnic Study of Atherosclerosis. ( 28220556 )
2017
50
Surgical Treatment of Obstructive Sleep Apnea on Cardiovascular Outcomes: A Systematic Review. ( 28923761 )
2017

Variations for Sleep Apnea

ClinVar genetic disease variations for Sleep Apnea:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 AHDC1 NM_001029882.3(AHDC1): c.2373_2374delTG (p.Cys791Trpfs) deletion Pathogenic rs587779766 GRCh37 Chromosome 1, 27876253: 27876254
2 AHDC1 NM_001029882.3(AHDC1): c.2898delC (p.Tyr967Thrfs) deletion Pathogenic rs587779767 GRCh37 Chromosome 1, 27875729: 27875729
3 AHDC1 NM_001029882.3(AHDC1): c.2547delC (p.Ser850Profs) deletion Pathogenic rs587779768 GRCh37 Chromosome 1, 27876080: 27876080

Expression for Sleep Apnea

Search GEO for disease gene expression data for Sleep Apnea.

Pathways for Sleep Apnea

Pathways related to Sleep Apnea according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.18 APOE CXCL8 EDN1 GHRL HCRT HTR2A
2
Show member pathways
13.46 ADIPOQ APOE CXCL8 IL6 INS LEP
3
Show member pathways
12.75 ADIPOQ IL6 INS LEP TNF
4
Show member pathways
12.41 ADIPOQ IGF1 INS LEP LEPR
6
Show member pathways
12.29 APOE CRP ICAM1 IL6 INS TNF
7
Show member pathways
12.19 ACE IGF1 IL6 TNF
8 12.16 CXCL8 HTR2A IL6 TNF
9
Show member pathways
12.13 EDN1 IGF1 NPPB TNF
10
Show member pathways
12.11 ACE GHRL IGF1 INS LEP REN
11 12.07 EDN1 ICAM1 NOS3 TNF
12 11.97 CXCL8 ICAM1 IL6 LEP TNF
13 11.96 CXCL8 ICAM1 IL6 TNF
14
Show member pathways
11.93 IL6 INS NOS3 TNF
15 11.92 EDN1 ICAM1 IL6 TNF
16 11.9 CXCL8 IGF1 IL6 INS
17 11.85 EDN1 IGF1 IL6 INS NOS3
18 11.82 CXCL8 ICAM1 IL6 TNF
19 11.81 ADIPOQ IGF1 IL6 INS LEP
20 11.77 CXCL8 ICAM1 IL6
21
Show member pathways
11.76 ACE NOS3 REN
22 11.73 CXCL8 IL6 TNF
23 11.7 ADIPOQ LEP LEPR TNF
24 11.66 ICAM1 IL6 TNF
25
Show member pathways
11.65 CXCL8 ICAM1 IL6 TNF
26 11.57 CXCL8 IL6 INS
27 11.57 CXCL8 IL6 TNF
28 11.55 ADIPOQ IGF1 IL6 INS LEP TNF
29 11.53 CXCL8 ICAM1 IL6 TNF
30 11.52 INS LEP LEPR
31 11.52 CXCL8 ICAM1 IL6 TNF
32 11.49 ICAM1 IL6 TNF
33 11.49 IGF1 IL6 INS
34 11.46 APOE IGF1 IL6 TNF
35 11.45 CXCL8 EDN1 IGF1 IL6 TNF
36 11.34 ICAM1 IL6 TNF
37 11.32 CXCL8 IL6 NOS3
38
Show member pathways
11.18 CRP EDN1 LEP LEPR
39 11.1 CXCL8 EDN1 ICAM1 IL6 NOS3 TNF
40 10.97 ADIPOQ IL6 LEP TNF
41 10.74 CRP CXCL8 IL6 TNF

GO Terms for Sleep Apnea

Cellular components related to Sleep Apnea according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 ACE ADIPOQ APOE CRP CXCL8 EDN1
2 extracellular space GO:0005615 9.5 ACE ADIPOQ APOE CRP CXCL8 EDN1

Biological processes related to Sleep Apnea according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.95 ADIPOQ EDN1 ICAM1 LEP
2 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.92 ICAM1 IL6 INS TNF
3 positive regulation of cytosolic calcium ion concentration GO:0007204 9.91 EDN1 GHRL HCRT HTR2A
4 cellular response to interleukin-1 GO:0071347 9.89 CXCL8 EDN1 ICAM1
5 cellular response to lipopolysaccharide GO:0071222 9.88 CXCL8 ICAM1 IL6 TNF
6 cellular response to drug GO:0035690 9.87 ADIPOQ EDN1 REN
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.87 IGF1 INS LEP
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 IGF1 IL6 LEP
9 response to glucocorticoid GO:0051384 9.86 ADIPOQ IL6 TNF
10 positive regulation of MAP kinase activity GO:0043406 9.85 EDN1 HTR2A TNF
11 glucose homeostasis GO:0042593 9.85 ADIPOQ INS LEP LEPR
12 response to nutrient levels GO:0031667 9.84 ADIPOQ GHRL LEP
13 negative regulation of fat cell differentiation GO:0045599 9.82 ADIPOQ IL6 TNF
14 positive regulation of MAPK cascade GO:0043410 9.81 IGF1 IL6 INS LEP
15 response to activity GO:0014823 9.8 ADIPOQ EDN1 LEP
16 negative regulation of endothelial cell proliferation GO:0001937 9.77 APOE GHRL TNF
17 acute-phase response GO:0006953 9.77 CRP IL6 INS
18 phosphatidylinositol 3-kinase signaling GO:0014065 9.74 EDN1 HTR2A IGF1
19 response to dietary excess GO:0002021 9.73 APOE LEP
20 positive regulation of glucose import GO:0046326 9.73 ADIPOQ IGF1 INS
21 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 EDN1 IGF1 IL6 TNF
22 sexual reproduction GO:0019953 9.72 LEP LEPR
23 negative regulation of blood vessel diameter GO:0097756 9.72 CRP INS
24 neutrophil mediated immunity GO:0002446 9.72 ACE IL6
25 response to leptin GO:0044321 9.72 EDN1 LEPR
26 glucose metabolic process GO:0006006 9.72 ADIPOQ GHRL INS LEP TNF
27 adult feeding behavior GO:0008343 9.71 GHRL LEP
28 artery smooth muscle contraction GO:0014824 9.71 EDN1 HTR2A
29 positive regulation of mitotic nuclear division GO:0045840 9.71 EDN1 IGF1 INS
30 negative regulation of hormone secretion GO:0046888 9.7 ADIPOQ EDN1
31 body fluid secretion GO:0007589 9.7 EDN1 NPPB
32 leptin-mediated signaling pathway GO:0033210 9.7 LEP LEPR
33 negative regulation of platelet activation GO:0010544 9.7 APOE NOS3
34 negative regulation of smooth muscle cell apoptotic process GO:0034392 9.68 EDN1 IGF1
35 ovulation from ovarian follicle GO:0001542 9.68 LEP NOS3
36 regulation of bone remodeling GO:0046850 9.67 LEP LEPR
37 negative regulation of hydrolase activity GO:0051346 9.67 LEPR NOS3
38 positive regulation of glycolytic process GO:0045821 9.67 HTR2A IGF1 INS
39 positive regulation of nitric oxide biosynthetic process GO:0045429 9.67